Immunovaccine Reports Positive Results from Ongoing Study of DepoVax(TM)-Based Anthrax Vaccines

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced positive results from an
immunogenicity study that evaluated anthrax vaccines formulated in the Company's
DepoVax(TM) platform. This study is part of an ongoing bio-defense research
program which was initiated in February 2012 to utilize Immunovaccine's
DepoVax(TM) adjuvanting technology in advancing the development of next
generation vaccines against the most threatening biological agents. Study
findings suggested that the DepoVax-based vaccines provided a more rapid and
long lasting immune response as compared to the licensed anthrax vaccine
BioThrax(TM). 


The study, which was conducted under the National Institute of Allergy and
Infectious Diseases' (NIAID) Preclinical Services Program, was designed to test
multiple DepoVax-formulated anthrax vaccines in non human primates, specifically
examining immunogenicity and safety after either one or two doses of the
vaccine. Study investigators compared the DepoVax-based vaccines to BioThrax,
the only commercially available anthrax vaccine. BioThrax requires at least two
doses to produce immune responses in animal models.


Preliminary study findings include:



--  A single dose of DepoVax-formulated anthrax vaccine produced sustained
    TNA (toxin-neutralizing antibody) titers detected in six of ten animals
    starting between day 21 and 49. Animals receiving one dose of Biothrax
    had no detectable TNA titers.

--  When a second dose of the DepoVax-formulated vaccine was delivered,
    there was a significant increase in anthrax TNAs in all immunized
    animals within one week of the booster administration.

--  Vaccination with the DepoVax-formulated vaccines resulted in no visible
    injection site reactions. Detailed microscopic examination showed robust
    immune cell infiltration to the site of vaccination. There was no
    evidence of systemic or local safety issues.



"Particularly impressive about these findings is the demonstration that
DepoVax-formulated vaccines generate toxin neutralizing antibodies with one
dose," said Dr. Marc Mansour, chief science officer of Immunovaccine. "These
findings suggest the potential for DepoVax to enable the development of an
effective and safe next generation anthrax vaccine." 


More studies with NIAID Preclinical Services are planned to begin in early 2013.
These will examine the ability of neutralizing antibody responses induced by a
DepoVax-based vaccine to protect animals from challenge with anthrax. 


The positive results from this immunogenicity study are consistent with previous
research conducted by Immunovaccine that demonstrated a DepoVax-based vaccine
was able to raise higher antibody levels, as compared to two doses of
alum-adjuvanted control vaccines. The persisting high antibody levels were
induced within four weeks following a single dose of anthrax antigen formulated
within DepoVax.


About DepoVax

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
Chief Science Officer
[phone]
[e-mail]
www.imvaccine.com


Vida Communication (media)
Tim Brons
[phone]
[e-mail]


Vida Communication (investors)
Stephanie Diaz
[phone]
[e-mail]


Brisco Capital Partners (Canadian investors)
Scott Koyich
[phone]
[e-mail]